AgingResearch.NewsJoin free

Phase 4Completed

A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma

Pharmacokinetic Study of Bortezomib (VELCADE) Administered Intravenously in Taiwanese Patients With Multiple Myeloma - A Post Approval Commitment Study

Sponsor
Johnson & Johnson Taiwan Ltd (Industry)
Enrollment
18 enrolled
Conditions
Multiple Myeloma
Interventions
Bortezomib
Ages
adults, older adults
Registry
NCT02268890

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to evaluate the pharmacokinetic (PK-the study of the way a drug enters and leaves the blood and tissues over time) characteristics of bortezomib when administered intravenously in Taiwanese participants with multiple myeloma (cancer of the types of cells normally found in bone marrow).

Primary outcomes

  • Initial Observed Plasma Drug Concentration (Co)
  • Maximum Observed Plasma Concentration (Cmax)
  • Area Under Plasma Concentration-Time Curve From Time 0 to Last Quantifiable Time Point
  • Area Under Plasma Concentration-Time Curve From Time 0 to Infinity (AUC-Infinity)

History

  1. Last registry update

  2. Primary completion

  3. Started

  4. Registered